Kristen Kurtz

Kristen Kurtz

Auto-generated profile, based on publicly available information

Kristen Kurtz

Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
CCCourtney Chambers
Courtney Chambers
KCKaterina Cermakova
Katerina Cermakova
YCYuen San Chan
Yuen San Chan
KKKristen Kurtz
Kristen Kurtz
KWKatharina Wohlan
Katharina Wohlan
HHH. Courtney Hodges
H. Courtney Hodges
In acute myeloid leukemia (AML), SWI/SNF chromatin remodeling complexes sustain leukemic identity by driving high levels of MYC. Previous studies have implicated the hematopoietic transcription factor PU.1 (SPI1) as an important target of SWI/SNF inhibition, but PU.1 is widely regarded to have pioneer-like activity. As a result, many questions have remained regarding the interplay between PU.1 and SWI/SNF in AML as well as normal hematopoiesis. Here we found that PU.1 binds to most of its targets in a SWI/SNF-independent manner and recruits SWI/SNF to promote accessibility for other AML core regulatory factors, including RUNX1, LMO2, and MEIS1. SWI/SNF inhibition in AML cells reduced DNA accessibility and binding of these factors at PU.1 sites and redistributed PU.1 to promoters. Analysis of nontumor hematopoietic cells revealed that similar effects also impair PU.1-dependent B-cell and monocyte populations. Nevertheless, SWI/SNF inhibition induced profound therapeutic response in an immunocompetent AML mouse model as well as in primary human AML samples. In vivo, SWI/SNF inhibition promoted leukemic differentiation and reduced the leukemic stem cell burden in bone marrow but also induced leukopenia. These results reveal a variable therapeutic window for SWI/SNF blockade in AML and highlight important off-tumor effects of such therapies in immunocompetent settings. Significance: Disruption of PU.1-directed enhancer programs upon SWI/SNF inhibition causes differentiation of AML cells and induces leukopenia of PU.1-dependent B cells and monocytes, revealing the on- and off-tumor effects of SWI/SNF blockade.

11 March 2022 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
KKKristen J. Kurtz
Kristen J. Kurtz
ETEran Tallis
Eran Tallis
AMAndrea N. Marcogliese
Andrea N. Marcogliese
RPRao H. Pulivarthi
Rao H. Pulivarthi
LPLorraine Potocki
Lorraine Potocki
ASAlexandra Stevens
Alexandra Stevens
Rubinstein-Taybi syndrome (RSTS) is a rare disorder characterized by developmental delay, short stature, dysmorphic facies and skeletal abnormalities. RSTS has been linked to a variety of malignant and benign tumors, but the frequency and characteristics of RSTS-related neoplasms remain unclear. We describe a unique case of near haploid B-cell lymphoblastic leukemia (B-ALL) in a 6-year-old girl with RSTS who harbors a likely pathogenic variant in CREBBP. Somatic CREBBP variants are enriched in some subsets of ALL; however, germline variants have not been previously described in childhood leukemia and may represent an underrecognized predisposition to malignancy. Our patient’s disease responded poorly to conventional chemotherapy and relapsed following a complete remission achieved with CD19 CAR T cell therapy. We propose that the constitutional CREBBP variant may have played a significant role in the leukemia’s resistance to chemotherapy and this patient’s poor response to therapy.

9 February 2022 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
LDLois M. Dodson
Lois M. Dodson
KKKristen J. Kurtz
Kristen J. Kurtz
AMAndrea N. Marcogliese
Andrea N. Marcogliese
BFBrian D. Friend
Brian D. Friend
ASAlexandra Stevens
Alexandra Stevens
KFKevin E. Fisher
Kevin E. Fisher
Familial platelet disorder with associated myeloid malignancy (FPD-MM) is an inherited disorder caused by germline mutations in the RUNX family transcription factor 1 (RUNX1) gene. FPD-MM is charac...